Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Cor Therapeutics Inc.
Bear, Stearns' Molowa repeated a "neutral" rating
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury